Dados B3 › AZTE3 × PRIO3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | AZTE3 | PRIO3 | year |
|---|---|---|---|
| ROE | 0.0% | 8.7% | 2025 |
| ROIC | -2.6%! | 2.5%! | 2025 |
| ROA | -4.3% | 3.8% | 2025 |
| Gross margin | 59.1% | 20.0% | 2025 |
| EBIT margin | -278.0%! | 11.6% | 2025 |
| Net margin | -343.0% | 14.4% | 2025 |
| Net debt/EBITDA | — | 3.27x | no year where both have it |
| Current ratio | 0.61x | 1.82x | 2025 |
| Revenue growth (1y) | 30.7% | 8.5% | 2025 |
| Revenue growth (5y CAGR) | — | 52.3% | no year where both have it |
| Piotroski F-Score | 4/9 | 4/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | AZTE3 | PRIO3 | year |
|---|---|---|---|
| P/E | — | 21.19x | 2025 |
| P/B | 0.56x | 1.85x | 2025 |
| EV/EBITDA | — | 9.49x | 2025 |
| FCF yield | -74.5% | 5.8% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:51 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it